GYRE - Gyre Therapeutics Inc Operating income before deduction of amortization

Graphic logo of gyretx.com (GYRE)

Gyre Therapeutics, Inc. (GYRE) generates revenue through licensing and the sale of liver fibrosis treatments, which drives the absolute cash results of its operations; the current parameter stands at 0.00. The company is implementing ESG standards regarding waste disposal and testing ethics, maintaining pricing power in China while expanding into Western markets. This chart helps identify trend reversals in a timely manner during periods of market cooling.

GYRE (Gyre Therapeutics) Operating profit EBITDA history from 11/23/2025 to 11/16/2026

Gyre Therapeutics Inc (GYRE) - metric breakdowns and financial figures

Fundamental company valuation:Gyre Therapeutics, Inc.
Brand item of Gyre Therapeutics

Investors must find a balance between operational risks and return on equity. Gyre Therapeutics, Inc. (GYRE) specializes in multi-year fibrosis therapy, which ensures long-term recurring revenue. Analyzing the EBITDA_Co chart allows for tracking daily cash inflows before taxes and interest. This indicator reveals the true scale of the business, separating organic growth from the impact of cheap financing. Stable price action confirms the resilience of the commercial model.